Patent classifications
A61P3/08
Composition and method for producing the same
A degradation product produced by degrading a composition containing a hyaluronic acid and a protein with a protease has a pain relieving effect, a joint function ameliorating effect, a cholesterol-lowering effect, a hypoglycemic effect and a diastolic blood pressure-lowering effect.
Composition and method for producing the same
A degradation product produced by degrading a composition containing a hyaluronic acid and a protein with a protease has a pain relieving effect, a joint function ameliorating effect, a cholesterol-lowering effect, a hypoglycemic effect and a diastolic blood pressure-lowering effect.
Modulation of GYS1 expression
Provided herein are methods, compounds, and compositions for reducing expression of GYS1 in an individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a glycogen storage disease or disorder in an individual in need.
Modulation of GYS1 expression
Provided herein are methods, compounds, and compositions for reducing expression of GYS1 in an individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a glycogen storage disease or disorder in an individual in need.
Use of Glucose Control Indicators for Risk Assessment and Treatment of Neurodevelopmental Disorders and Techniques for Establishing the Status of Chronic Glucose Control
Dysglycemia as a risk factor for neurodevelopmental disorder or developmental diabetes. The risk is assessed based on measurement of a glucose control indicator in a blood sample. One particular example of a neurodevelopmental disorder is retinopathy of prematurity in an infant. One particular example of a glucose control indicator is ‘comprehensive glycated hemoglobin fraction’ or ‘comprehensive glycated albumin fraction.’ This is calculated using ‘total whole blood protein’ in the denominator. In the case of chronic hyperglycemia, there is an increased risk of proliferative retinopathy of prematurity. In the case of chronic hypoglycemia, there is an increased risk of non-proliferative retinopathy of prematurity. This ‘total whole blood protein’ technique could also be used to determine the glucose control status in other types of patients.
Multifiber prebiotic composition for digestive health, weight control, boosting immunity and improving health
A composition composed of xylooligosaccharide, arabinogalactan, inulin, Ganoderma lucidum beta glucan, insoluble yeast β (1, 3/1, 6)-glucan, soluble oat β (1,3/1, 4)-glucan, and insoluble dried Saccharomyces cerevisiae fermentate, with a Bacillus coagulans component, for use in improving or maintaining digestive health, weight and glucose balance and boosting immunity is provided.
ISOLATION OF BONA FIDE PANCREATIC PROGENITOR CELLS
The present invention relates to a method for isolating bona fide pancreatic progenitor cells and to cell populations enriched for bona fide pancreatic progenitor cells.
ISOLATION OF BONA FIDE PANCREATIC PROGENITOR CELLS
The present invention relates to a method for isolating bona fide pancreatic progenitor cells and to cell populations enriched for bona fide pancreatic progenitor cells.
SUBLINGUAL EPINEPHRINE FORMULATIONS AND METHODS OF USE
The present disclosure provides epinephrine formulations and methods of treating anaphylaxis, methods for concomitant therapy during a cardiac event, methods for treating hypoglycemia, and a prophylactic method for immunotherapy, using the epinephrine formulations disclosed herein. The epinephrine formulations of the present disclosed are formulated for delivery via the oral mucosa. Epinephrine formulations of the present disclosure may further comprise citric acid to improve delivery of epinephrine through the oral mucosa. The epinephrine formulations of the present disclosure induce a robust, global sympathetic response in a subject that is disproportionate to the serum epinephrine concentration in the subject.
SUBLINGUAL EPINEPHRINE FORMULATIONS AND METHODS OF USE
The present disclosure provides epinephrine formulations and methods of treating anaphylaxis, methods for concomitant therapy during a cardiac event, methods for treating hypoglycemia, and a prophylactic method for immunotherapy, using the epinephrine formulations disclosed herein. The epinephrine formulations of the present disclosed are formulated for delivery via the oral mucosa. Epinephrine formulations of the present disclosure may further comprise citric acid to improve delivery of epinephrine through the oral mucosa. The epinephrine formulations of the present disclosure induce a robust, global sympathetic response in a subject that is disproportionate to the serum epinephrine concentration in the subject.